{"id":3654,"date":"2025-09-02T19:19:16","date_gmt":"2025-09-02T22:19:16","guid":{"rendered":"https:\/\/stemcelltherapyargentina.com\/the-critical-role-of-tissue-factor-in-the-endovenous-safety-of-mesenchymal-stem-cell-therapies\/"},"modified":"2026-03-27T15:08:11","modified_gmt":"2026-03-27T18:08:11","slug":"the-critical-role-of-tissue-factor-in-the-endovenous-safety-of-mesenchymal-stem-cell-therapies","status":"publish","type":"post","link":"https:\/\/stemcelltherapyargentina.com\/en\/the-critical-role-of-tissue-factor-in-the-endovenous-safety-of-mesenchymal-stem-cell-therapies\/","title":{"rendered":"The Critical Role of Tissue Factor in the Endovenous Safety of Mesenchymal Stem Cell Therapies"},"content":{"rendered":"\n<p><\/p>\n\n<p><strong>Introduction<\/strong><\/p>\n\n<p>Mesenchymal stem cell (MSC) therapies have established themselves as a mainstay of regenerative medicine, offering hope for treating everything from autoimmune diseases to tissue damage and even &#8220;anti-aging&#8221; effects. These cells, capable of modulating immune responses, promoting tissue regeneration and differentiating into various cell types, are being evaluated in hundreds of clinical trials around the world. However, the diversification of MSC products-derived from bone marrow, adipose tissue, umbilical cord and other tissues-has raised significant concerns about their safety, especially when administered intravascularly. A key factor in these concerns is <strong>tissue factor (TF, or CD142)<\/strong>, a protein that can trigger dangerous blood clotting events. Based on two seminal studies (Hoang et al., 2024, and Moll et al., 2019), this blog explores the role of TF in MSC-induced hypercoagulation, the variability of these cellular products, and the urgent need for new clinical guidelines to ensure safer therapies.    <\/p>\n\n<p><strong>The Promise and Risks of MSC Therapies<\/strong><\/p>\n\n<p>MSCs, present in tissues such as bone marrow (BM), adipose tissue (AT), dental pulp (DP) and umbilical cord (UC), are valued for their regenerative potential. They secrete growth factors that stimulate blood vessel formation, reduce inflammation and promote tissue repair, making them versatile tools in regenerative medicine. Clinical trials have shown that bone marrow-derived MSCs are generally safe in both autologous (patient&#8217;s own) and allogeneic (donor) settings. However, this cannot be assumed for new MSC products derived from adipose or perinatal tissues, which have gained popularity due to their accessibility and scalability.   <\/p>\n\n<p>The main problem lies in the interaction of MSCs with blood when administered intravascularly, the most common delivery route. Upon contact with the blood, MSCs can activate the coagulation system, increasing the risk of <strong>thrombosis<\/strong>, such as pulmonary embolisms or venous thromboembolisms, which can be fatal. This phenomenon, known as an <strong>instantaneous blood-mediated inflammatory reaction (IBMIR)<\/strong>, is largely driven by the expression of <strong>tissue factor (TF)<\/strong>, a protein that initiates the extrinsic coagulation pathway.  <\/p>\n\n<p><strong>Tissue Factor: A Double-Edged Weapon<\/strong><\/p>\n\n<p>Tissue factor is a key player in blood coagulation. Under normal conditions, TF is found in cells not exposed to blood flow, such as subendothelial cells or fibroblasts. When there is injury to blood vessels, TF interacts with clotting factors such as FVII and FX, triggering a cascade that leads to the formation of fibrin clots. However, MSCs, especially those derived from sources other than bone marrow, can express high levels of TF, which poses a significant risk when infused into the bloodstream.   <\/p>\n\n<p>According to the study by Hoang et al. (2024), published in <em>Stem Cell Research &amp; Therapy<\/em>, MSCs from different tissue sources show varying levels of TF expression: <\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Umbilical cord (UC) MSCs<\/strong> and <strong>adipose tissue (AT) MSCs<\/strong> express the highest levels of TF, followed by <strong>dental pulp (DP) MSCs<\/strong>, while <strong>bone marrow (BM) MSCs<\/strong> show the lowest expression.<\/li>\n\n\n\n<li>UC and AT MSCs also express elevated levels of the procoagulant factor <strong>COL1A1<\/strong> and <strong>phosphatidylserine (PS)<\/strong> on their surface, further enhancing their clotting capacity.<\/li>\n\n\n\n<li>Environmental factors such as cell density, hypoxia or inflammation significantly influence TF expression, complicating in vitro predictions of its behavior in vivo.<\/li>\n<\/ul>\n\n<p>Meanwhile, Moll et al. (2019), published in <em>Trends in Molecular Medicine<\/em>, highlight that TF is the main determinant of MSCs&#8217; <strong>hemocompatibility-that<\/strong> is, their ability to interact with blood without triggering adverse reactions. Their meta-analysis highlights that variability in TF expression among different types of MSCs can have &#8220;potential lethal consequences&#8221; when administered systemically. For example, Hoang et al. cite cases of serious thrombotic events, such as pulmonary embolisms in patients treated with adipose tissue MSCs and venous thromboembolisms in those who received umbilical cord MSCs.    <\/p>\n\n<p><strong>The Coagulation Challenge: Evidence from Clinical and Preclinical Studies.<\/strong><\/p>\n\n<p>Hoang et al. performed a comprehensive study on MSCs cultured under xeno- and serum-free conditions, analyzing their coagulant activity and TF expression. Their findings include:  <\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>In vitro coagulation tests<\/strong>: MSCs from all sources (AT, BM, DP, UC) induced fibrin clots in healthy plasma, with AT MSCs showing the highest coagulant activity, followed by UC, DP and BM MSCs. Interestingly, a TF inhibitory antibody only partially suppressed this coagulation, suggesting that other factors, such as COL1A1 and PS, contribute to the process. <\/li>\n\n\n\n<li><strong>Clinical observations<\/strong>: In patients receiving umbilical cord MSC infusions, intravenous administration caused a transient increase in <strong>D-dimer<\/strong> levels (a marker of clot formation and dissolution), while intrathecal administration (into the spinal space) showed stable D-dimer levels. This indicates that the route of administration significantly impacts thrombogenic risk. <\/li>\n\n\n\n<li><strong>No direct correlation<\/strong>: Surprisingly, no clear relationship was found between TF expression levels and coagulation markers such as D-dimer, suggesting that TF alone cannot predict the risk of hypercoagulation.<\/li>\n<\/ul>\n\n<p>Moll et al. reinforce that the diversification of MSC products in the last decade makes it inappropriate to extrapolate safety data from bone marrow MSCs to new products. They argue that variability in TF expression among MSC types requires routine hemocompatibility testing for all cellular products intended for intravascular administration.  <\/p>\n\n<p><strong>Environmental Influences on TF Expression<\/strong><\/p>\n\n<p>A key finding of Hoang et al. is that TF expression is not static. Factors such as:  <\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Cell density<\/strong>: Higher cell density in culture reduces TF expression, possibly due to cell-cell interactions.<\/li>\n\n\n\n<li><strong>Hypoxia<\/strong>: Low oxygen levels, common in certain tissue microenvironments, can increase TF expression.<\/li>\n\n\n\n<li><strong>Inflammation<\/strong>: Cytokines such as TNF\u03b1 and IFN\u03b3, present in inflammatory conditions, can modulate TF levels.<\/li>\n\n\n\n<li><strong>Storage conditions<\/strong>: Prolonged storage of MSC in infusion solutions (such as NaCl or lactated Ringer&#8217;s lactate) may alter TF expression and cell viability, affecting their coagulant activity.<\/li>\n<\/ul>\n\n<p>These results highlight a critical challenge: in vitro testing may not accurately reflect how MSCs behave in the bloodstream, where environmental factors such as inflammation or calcium levels can amplify TF-mediated coagulation.<\/p>\n\n<p><strong>Strategies for Safer MSC Therapies<\/strong><\/p>\n\n<p>Both studies propose practical strategies to mitigate the risks of MSC-induced thrombosis:<\/p>\n\n<ol class=\"wp-block-list\">\n<li><strong>Hemocompatibility Testing<\/strong>: Moll et al. advocate routine monitoring of TF expression in all MSC products intended for intravascular use. This includes assessing TF levels by flow cytometry, real-time PCR, and functional assays such as FXa quantification.  <\/li>\n\n\n\n<li><\/li>\n\n\n\n<li><strong>Alternative Routes of Administration<\/strong>: Local administration, such as intrathecal administration, significantly reduces the risk of hypercoagulation compared to intravenous infusion, as it avoids direct contact with the bloodstream.<\/li>\n\n\n\n<li><strong>Monitoring of Coagulation Indicators<\/strong>: The Hoang et al. trials highlight the importance of monitoring markers such as D-dimer, fibrinogen, activated partial thromboplastin time (aPTT), prothrombin time (PT) and thrombin time (TT) before and after MSC infusions to detect and manage any signs of hypercoagulation. <\/li>\n\n\n\n<li><strong>Innovations in Products and Processes<\/strong>: Moll et al. suggest that, by recognizing the hemocompatibility problem, innovations such as the selection of MSCs with low TF expression, the use of specific TF inhibitors or the optimization of culture and storage conditions to minimize coagulant activity can be developed. <\/li>\n<\/ol>\n\n<p><strong>The Need for New Clinical Guidelines<\/strong><\/p>\n\n<p>The diversification of MSC products, along with variability in the expression of TF and other procoagulant factors, underscores the urgent need for new clinical guidelines. Moll et al. argue that current guidelines, based primarily on bone marrow MSC data, are not sufficient to address the risks associated with new cellular products. They propose a standardized approach to assess hemocompatibility, including:   <\/p>\n\n<ul class=\"wp-block-list\">\n<li><strong>Mandatory TF testing<\/strong>: All MSC products must undergo TF expression and activity testing prior to clinical use.<\/li>\n\n\n\n<li><strong>Optimized management protocols<\/strong>: Guidelines should specify best practices for management, prioritizing local routes when possible.<\/li>\n\n\n\n<li><strong>Risk mitigation strategies<\/strong>: Prophylactic use of anticoagulants and continuous monitoring should be standard requirements in clinical trials and clinical practice.<\/li>\n\n\n\n<li><\/li>\n<\/ul>\n\n<p><strong>Conclusion<\/strong><\/p>\n\n<p>Mesenchymal stem cell therapies represent an exciting frontier in regenerative medicine, but their safety depends on addressing the risks associated with hypercoagulation, particularly those mediated by tissue factor. Studies by Hoang et al. (2024) and Moll et al. (2019) highlight that variability in TF expression between different MSC sources, combined with environmental influences, requires a more rigorous approach to ensure patient safety. Strategies such as hemocompatibility testing, local administration, and continuous monitoring of coagulation markers are essential to minimize thrombogenic risks. As the MSC field continues to evolve, the adoption of new clinical guidelines will be crucial to maximize the benefits of these therapies while protecting patient health.     <\/p>\n\n<p><strong>Sources<\/strong><\/p>\n\n<ol class=\"wp-block-list\">\n<li>Hoang, V. T., et al. (2024). Impact of tissue factor expression and administration routes on thrombosis development induced by mesenchymal stem\/stromal cell infusions: re-evaluating the dogma. <em>Stem Cell Research &amp; Therapy, 15<\/em>(56). https:\/\/doi.org\/10.1186\/s13287-023-03582-3<\/li>\n\n\n\n<li>Moll, G., et al. (2019). Intravascular mesenchymal stromal\/stem cell therapy product diversification: Time for new clinical guidelines. <em>Trends in Molecular Medicine, 25<\/em>(2), 149-163. https:\/\/doi.org\/10.1016\/j.molmed.2018.12.006<\/li>\n<\/ol>\n\n<p><strong>Note to the reader<\/strong>: This blog is designed to inform and educate on the complex topic of regenerative medicine to groups of inexperienced physicians who promote this therapy in an inappropriate manner with strong profit-making activities. If you are considering stem cell therapy, always consult with qualified medical professionals and review updated clinical guidelines. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Introduction Mesenchymal stem cell (MSC) therapies have established themselves as a mainstay of regenerative medicine, offering hope for treating everything from autoimmune diseases to tissue damage and even &#8220;anti-aging&#8221; effects. These cells, capable of modulating immune responses, promoting tissue regeneration and differentiating into various cell types, are being evaluated in hundreds of clinical trials around [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3654","post","type-post","status-publish","format-standard","hentry","category-sin-categorizar"],"_links":{"self":[{"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/posts\/3654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/comments?post=3654"}],"version-history":[{"count":1,"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/posts\/3654\/revisions"}],"predecessor-version":[{"id":3656,"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/posts\/3654\/revisions\/3656"}],"wp:attachment":[{"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/media?parent=3654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/categories?post=3654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stemcelltherapyargentina.com\/en\/wp-json\/wp\/v2\/tags?post=3654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}